Silo Pharma won a European patent for its lead PTSD candidate SPC-15, a preventative intranasal, nose-to-brain therapy targeting stress-induced psychiatric disorders.
The EPO granted EP3952852, covering methods using selected 5-HT4 receptor agonists administered before extreme stress exposure to prevent fear or depressive-like behavior.
The company holds an exclusive license from Columbia University for the European patent, supporting its plan to develop and commercialize SPC-15 globally.
SILO•
